*Refresh the page if the below document does not appear.
Sanofi sees rapid profit growth on its Flu Vaccine Dupixent
The french drugmaker Sanofi in its forecast said that it is now expecting faster earnings growth this financial year on account of strong demand for its bestselling drug ‘Dupixent’ and for its flu vaccines.
AHF accuses "Greediad" Gilead over hike in HIV/AIDS drug prices
The AHF (AIDS Healthcare Foundation) group caregivers hit out at the California-based Drugmaker Gilead Sciences and accused them of being ‘Greediad’ as they refused to offer the 340B discount price for HIV drugs to providers who use contract pharmacies.
NPPA fixes retail price of Dapagliflozin and Sitagliptin combination drug
The Multi-Disciplinary Committee (MDC) of experts, which is the advisory committee to NPPA (National Pharmaceutical Pricing Authority) recently has taken the step of fixing the retail price of anti-Diabetes drug combination comprising of sitagliptin and dapagliflozin.
Favourable time for Indian Pharma to increase investments in R&D
Since, there is a large number of drugs going off-patent in the next 10 years including Biologics which are high-value products. If interested in Biosimilars, this is the right time for Indian Pharma companies to invest in the R&D if they wish to make proper use of the opportunities.
GSK to jump over regulatory submissions as arthritis drug failed to meet key goal
GSK announced that it would not be moving forward with the regulatory submissions of its experimental drug after it failed to meet a key goal in a late-stage study. The drug named “otilimab” was indicated for the treatment of moderate-to-severe Rheumatoid Arthritis (RA).
US FDA points out Quality and procedural lapses at Lupin's Pune unit
The US regulatory authority conducted a priorapproved inspection of Lupin’s biotech manufacturing facility in Pune earlier this month and issued a form 483 with 17 observations. The company said in a statement that it won’t be having any effect on the revenue generated by the operations of the unit.
Study affirms higher risk of rare blood-clot associated with AstraZeneca's COVID-19 Jab
On Thursday, a large international study
announced that AstraZeneca’s COVID-19
vaccine has been linked to 30% higher risk of
getting a very rare blood-clotting condition
when compared to the Pfizer COVID-19
Vaccine.
